In a proclamation published on April 2, 2026, the White House announced that it was imposing Section 232 tariffs of 100% on patented pharmaceuticals and their ingredients.

These tariffs will have different rates for countries that have signed trade deals with the U.S., including the European Union, Japan, South Korea, and Switzerland at 15%. The United Kingdom with have a rate of 10%. Generic pharmaceuticals will not be subject to tariffs at this time.

Companies that have a plan to onshore production of pharmaceuticals and pharmaceutical ingredients that is approved by the Secretary of Commerce will granted a 20% duty rate for 4 years.

These tariffs will come into effect in “20 days for certain large companies, and 180 days for smaller companies.”

The “Adjusting Imports of Pharmaceuticals and Pharmaceutical ingredients into the United States” Proclamation can be found here:
https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/

The accompanying Fact Sheet can be found here:
https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/